
NSPXD
US listing · $693,866 market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2017
EPS trend, 90 days to now · +100.0% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Aug 16, 2021 | Time not confirmed | — | 0.45 | — |
| May 14, 2021 | Time not confirmed | — | -3.64 | — |
| Nov 24, 2020 | Time not confirmed | — | -0.02 | — |
| Aug 17, 2020 | Time not confirmed | — | -17.62 | — |
| May 15, 2020 | Time not confirmed | — | -26.74 | — |
| Feb 26, 2020 | Time not confirmed | — | -129.42 | — |
| Nov 15, 2019 | Time not confirmed | — | 3946.87 | — |
| Aug 12, 2019 | Time not confirmed | — | -314.25 | — |
| May 10, 2019 | Time not confirmed | — | -29.21 | — |
| Feb 27, 2019 | Time not confirmed | — | 1404.19 | — |
| Nov 16, 2018 | Time not confirmed | — | -8271.82 | — |
| Aug 13, 2018 | Time not confirmed | — | -97.88 | — |
| May 14, 2018 | Time not confirmed | — | -1230.27 | — |
Rebus Holdings, Inc. focuses on the research and development of precision therapeutics for the treatment of cancer. Its lead asset is RT-AR001, an adenosine receptor antagonist for tumor infiltration and enhanced outcomes when administered intra-tumorally. The company is based in Westlake Village, California.
| Feb 28, 2018 |
| Time not confirmed |
| — |
| -28200.09 |
| — |